Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2
Metadatos
Afficher la notice complèteAuteur
Pérez-Jurado, Luis A.; Cáceres, Alejandro; Balagué-Dobón, Laura; Esko, Tonu; López de Heredia, Miguel; Quintela, Inés; Cruz, Raquel; Lapunzina, Pablo; Carracedo, Ángel; SCOURGE Cohort Group; González, Juan R.Editorial
Springer Nature
Date
2024-02-19Referencia bibliográfica
Pérez-Jurado, L.A., Cáceres, A., Balagué-Dobón, L. et al. Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2. Commun Biol 7, 202 (2024). https://doi.org/10.1038/s42003-024-05805-6
Patrocinador
Catalan Department of Economy and Knowledge (SGR2017/1974, SGR2017/801); Spanish Ministry of Science (MDM-2014-0370), (CEX2018-000806-S); Fondo Europeo de Desarrollo Regional, UE (RTI2018-100789-B-I00); Estonian Research Council (PUT1660); Instituto de Salud Carlos III (COV20_00622); European Union (ERDF); Amancio Ortega Foundation; Banco de Santander; Generalitat de CatalunyaRésumé
The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people.